Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Jabbour Discusses Blinatumomab in ALL

August 2nd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia.

FDA Grants Quizartinib Breakthrough Designation for FLT3-ITD+ AML

August 1st 2018

The FDA has granted a breakthrough therapy designation to quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

Dr. Smith Discusses Double-Hit and Triple-Hit Lymphoma

July 31st 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses double-hit and triple-hit lymphoma.

EU Panel Backs Frontline Daratumumab/VMP Combo for Multiple Myeloma

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Pollyea Discusses Recent Advances in AML

July 27th 2018

Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses recent advances in the treatment landscape of acute myeloid leukemia.

Dr. Ansell Discusses Immune Evasion in Lymphoma

July 27th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

July 26th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

Dr. Goy on the Evolution of Treatment in Mantle Cell Lymphoma

July 26th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).

Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

July 24th 2018

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.

Dr. Kurtz on the Clinical Utility of Cell-Free DNA in Lymphoma

July 24th 2018

David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses the utility of cell-free DNA in lymphoma.

Dr. Hutchings on the Aim of the ECHELON-1 Study in Hodgkin Lymphoma

July 24th 2018

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses the aim of the ECHELON-1 study in classical Hodgkin lymphoma.

Lenalidomide/Rituximab Improves PFS in Phase III Indolent Lymphoma Study

July 24th 2018

Combining lenalidomide with rituximab significantly improved progression-free survival compared with rituximab alone for the treatment of patients with relapsed/refractory indolent lymphoma.

Goy Discusses Latest Lymphoma Data

July 24th 2018

Andre Goy, MD, discusses some of the most important lymphoma data presented at the 2018 ASCO Annual Meeting and potential future directions for treatment.

Dr. Lunning Discusses the Treatment of Peripheral T-Cell Lymphoma

July 23rd 2018

Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the treatment of patients with peripheral T-cell lymphoma.

Ibrutinib/Rituximab Emerges as New Standard in Waldenstrom Macroglobulinemia

July 23rd 2018

Results from the phase III iNNOVATE trial established the combination of ibrutinib plus rituximab as the new standard of care in Waldenström macroglobulinemia.

Dr. Hobbs on the Updated NCCN Guidelines in CML

July 20th 2018

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).

Dr. Brander on the Treatment Landscape for Patients With High-Risk CLL

July 20th 2018

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

Dr. Smith Discusses Brentuximab Vedotin in CTCL

July 20th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.

Ansell Discusses Combination Potential in Hodgkin Lymphoma

July 20th 2018

Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.

FDA Approves Ivosidenib for IDH1+ AML

July 20th 2018

The FDA has approved ivosidenib for the treatment of adult patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.